Following on from information provided to NICE by the company in June 2016, the appraisal of Drisapersen for the first-line treatment of Duchenne’s muscular dystrophy [ID911] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | HST |
| ID number | 911 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 November 2022 | Discontinued. Following on from information provided to NICE by the company in June 2016, the appraisal of Drisapersen for the first-line treatment of Duchenne’s muscular dystrophy [ID911] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 28 June 2016 | Suspended. NICE is considering an evaluation of drisapersen for treating Duchenne muscular dystrophy. The Institute has now been informed by the company that it has withdrawn its Marketing Authorisation for drisapersen in this indication, from the European Medicines Agency. Therefore, NICE has decided to suspend this evaluation on its current work programme. As this topic has been referred to the Institute we will continue to monitor any development |
| 28 June 2016 | Draft scope documents |
For further information on our processes and methods, please see our CHTE processes and methods manual